Lymphoma, Mantle-Cell Clinical Trials

59 clinical trials for Lymphoma, Mantle-Cell across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — RECRUITING · PHASE1
• Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma — RECRUITING · PHASE2
• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event — RECRUITING · NA
• A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer — RECRUITING · PHASE1
• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies — RECRUITING · PHASE1
• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma — RECRUITING · PHASE2
• Study of Oral LOXO-338 in Patients With Advanced Blood Cancers — COMPLETED · PHASE1
• A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL — ACTIVE_NOT_RECRUITING · PHASE3
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — ACTIVE_NOT_RECRUITING · PHASE3
• Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells — ACTIVE_NOT_RECRUITING
• A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies — NOT_YET_RECRUITING · NA
• A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) — COMPLETED · PHASE2
• Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL — COMPLETED · PHASE2
• A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma — COMPLETED · PHASE2
• A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) — COMPLETED · PHASE2
• A Phase 1 Study of ADI-001 in B Cell Malignancies — TERMINATED · PHASE1
• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion — COMPLETED · PHASE4
• A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea — COMPLETED
• A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma — COMPLETED
• An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma — TERMINATED · PHASE2
• Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India — COMPLETED
• Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma — WITHDRAWN · PHASE1
• Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer — OTHER
• Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] — COMPLETED
• This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma — NOT_YET_RECRUITING · PHASE2
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors — TERMINATED · PHASE1
• A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma — WITHDRAWN · PHASE3
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma — COMPLETED · PHASE1
• Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma — COMPLETED · PHASE2
• EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma — COMPLETED · PHASE2
• A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice — COMPLETED
• Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL — COMPLETED · PHASE1
• Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma — COMPLETED · PHASE1
• Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma — OTHER · PHASE1
• Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL — NOT_YET_RECRUITING · PHASE2
• Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy — COMPLETED · PHASE2
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) — COMPLETED · PHASE1
• Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants — COMPLETED
• A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers — COMPLETED
• Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL — COMPLETED · PHASE2
• Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma — COMPLETED · PHASE2
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies — COMPLETED · PHASE1
• A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) — COMPLETED · PHASE2
• A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies — TERMINATED · PHASE1
• A Safety Study of SGN-CD19A for B-Cell Lymphoma — COMPLETED · PHASE1
• Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) — TERMINATED · PHASE2
• Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL — OTHER · PHASE3
• Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment — COMPLETED
• Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma — COMPLETED · PHASE2
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS — COMPLETED · PHASE2

Refine this search